LSV Asset Management Decreases Stake in Sabra Healthcare REIT, Inc. $SBRA

LSV Asset Management lowered its stake in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) by 4.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,618,915 shares of the real estate investment trust’s stock after selling 153,400 shares during the period. LSV Asset Management’s holdings in Sabra Healthcare REIT were worth $67,457,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Oppenheimer & Co. Inc. increased its stake in shares of Sabra Healthcare REIT by 1.7% in the third quarter. Oppenheimer & Co. Inc. now owns 33,984 shares of the real estate investment trust’s stock worth $633,000 after buying an additional 581 shares during the period. State of Michigan Retirement System grew its holdings in Sabra Healthcare REIT by 1.1% in the 2nd quarter. State of Michigan Retirement System now owns 57,249 shares of the real estate investment trust’s stock worth $1,056,000 after acquiring an additional 600 shares during the last quarter. Amalgamated Bank grew its holdings in Sabra Healthcare REIT by 0.6% in the 3rd quarter. Amalgamated Bank now owns 105,159 shares of the real estate investment trust’s stock worth $1,960,000 after acquiring an additional 612 shares during the last quarter. Cherry Creek Investment Advisors Inc. increased its position in shares of Sabra Healthcare REIT by 4.4% in the second quarter. Cherry Creek Investment Advisors Inc. now owns 19,074 shares of the real estate investment trust’s stock valued at $352,000 after acquiring an additional 802 shares during the period. Finally, Ethos Financial Group LLC raised its stake in shares of Sabra Healthcare REIT by 1.3% during the second quarter. Ethos Financial Group LLC now owns 66,658 shares of the real estate investment trust’s stock valued at $1,229,000 after acquiring an additional 835 shares during the last quarter. Institutional investors own 99.40% of the company’s stock.

Sabra Healthcare REIT Stock Up 3.3%

SBRA stock opened at $20.25 on Friday. Sabra Healthcare REIT, Inc. has a fifty-two week low of $15.60 and a fifty-two week high of $20.27. The company has a market capitalization of $5.05 billion, a price-to-earnings ratio of 28.13, a price-to-earnings-growth ratio of 1.36 and a beta of 0.67. The business’s 50 day moving average price is $19.02 and its two-hundred day moving average price is $18.75. The company has a debt-to-equity ratio of 0.92, a quick ratio of 5.19 and a current ratio of 5.19.

Sabra Healthcare REIT (NASDAQ:SBRA) last released its earnings results on Thursday, February 12th. The real estate investment trust reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.01. Sabra Healthcare REIT had a return on equity of 6.38% and a net margin of 23.50%.The company had revenue of $201.35 million during the quarter, compared to analysts’ expectations of $201.97 million. During the same quarter last year, the business posted $0.36 EPS. The firm’s revenue for the quarter was up 16.2% compared to the same quarter last year. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. As a group, analysts forecast that Sabra Healthcare REIT, Inc. will post 1.45 earnings per share for the current fiscal year.

Sabra Healthcare REIT Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 27th. Shareholders of record on Friday, February 13th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $1.20 annualized dividend and a yield of 5.9%. Sabra Healthcare REIT’s dividend payout ratio (DPR) is currently 166.67%.

Key Stories Impacting Sabra Healthcare REIT

Here are the key news stories impacting Sabra Healthcare REIT this week:

• Positive Sentiment: Management issued strong FY‑2026 EPS guidance of $1.55–$1.59, well above the cited consensus of $1.06, which is the primary bullish catalyst for the stock as it implies meaningful earnings acceleration. Sabra Reports Fourth Quarter 2025 Results; Introduces 2026 Guidance
• Positive Sentiment: Reported Q4 EPS of $0.38 beat the $0.37 consensus by $0.01; revenue was essentially flat with estimates and grew ~16% year‑over‑year, showing underlying top‑line momentum. Q4 Press Release / Slides
• Positive Sentiment: FFO/AFFO metrics for Q4 (FFO $0.36; normalized AFFO ~$0.38) and improved revenue mix (noted strength in SHOP segments) support the higher guidance and the dividend outlook. Sabra: Q4 Earnings Snapshot
• Neutral Sentiment: The company issued a 2026 outlook and dividend update alongside results; dividend confirmation is supportive but already priced in for yield‑sensitive REIT investors. Sabra Healthcare REIT Issues 2026 Outlook and Dividend
• Negative Sentiment: A BMO analyst kept a cautious/hold stance, pointing to a softer FFO outlook in some segments and uncertainty around an RCA loan exposure (credit/collection risk), which increases downside risk if those issues persist. Analyst Note: Hold Rating Cites FFO/Loan Uncertainty
• Negative Sentiment: Though EPS beat was marginal, revenue narrowly missed estimates — a reminder that operational execution and FFO conversion matter for REIT valuation, and any future misses could weigh on the shares. Q4 Press Release / Slides

Analyst Ratings Changes

Several research firms recently issued reports on SBRA. Weiss Ratings reissued a “buy (b)” rating on shares of Sabra Healthcare REIT in a research note on Thursday, January 22nd. National Bank Financial set a $22.00 price target on Sabra Healthcare REIT in a research report on Friday, October 17th. Truist Financial lifted their price objective on Sabra Healthcare REIT from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Tuesday, January 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $22.00 price target on shares of Sabra Healthcare REIT in a research note on Monday, December 15th. Finally, UBS Group began coverage on shares of Sabra Healthcare REIT in a report on Tuesday, November 18th. They issued a “neutral” rating and a $20.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $21.11.

Sabra Healthcare REIT Company Profile

Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.